# A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole

> **NCT01627587** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 46 (actual)

## Conditions studied

- Obstetric Labour, Premature

## Interventions

- **DRUG:** GSK221149 750 mg
- **DRUG:** Ketoconazole
- **DRUG:** GSK221149 100 mg
- **DRUG:** GSK221149 750 mg Fasted
- **DRUG:** GSK221149 750 mg + Food

## Key facts

- **NCT ID:** NCT01627587
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-12
- **Primary completion:** 2012-02-09
- **Final completion:** 2012-02-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627587, "A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01627587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*